Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Roth

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|May 20, 2024
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature ReviewGrace E Fox, Mark Bernauer, Jennifer M Stephens, et al.
Public Health Genomics|April 22, 2010
Stakeholder perspectives on a risk-benefit framework for genetic testingJoshua A Roth, Louis P Garrison, Wylie Burke, et al.
Journal of Managed Care & Specialty Pharmacy|September 27, 2019
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast CancerNaomi R M Schwartz, Meghan R Flanagan, Joseph B Babigumira, et al.
Journal of Comparative Effectiveness Research|March 21, 2014
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancerJoshua A Roth, Mark E Bensink, Paul V O'Donnell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 21, 2021
Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset DiabetesNaomi R M Schwartz, Lynn M Matrisian, Eva E Shrader, et al.
Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.
Future Oncology (London, England)|June 12, 2024
A descriptive analysis of real-world oncology biosimilar use in JapanJoshua A Roth, Makan Rahshenas, Grégoire Nowacki, et al.
JPGN Reports|May 11, 2023
Assessing Barriers to use of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease: A Qualitative StudyNaomi R M Schwartz, Savannah R McNichol, Beth Devine, et al.
Journal of Oncology Practice|May 7, 2015
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in MedicareJoshua A Roth, Sean D Sullivan, Bernardo H L Goulart, et al.
Plos One|October 1, 2019
Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiariesLia M Halasz, Shilpen A Patel, Jean A McDougall, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Clinicoeconomics and Outcomes Research : CEOR|May 20, 2024
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature ReviewGrace E Fox, Mark Bernauer, Jennifer M Stephens, et al.
Public Health Genomics|April 22, 2010
Stakeholder perspectives on a risk-benefit framework for genetic testingJoshua A Roth, Louis P Garrison, Wylie Burke, et al.
Journal of Managed Care & Specialty Pharmacy|September 27, 2019
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast CancerNaomi R M Schwartz, Meghan R Flanagan, Joseph B Babigumira, et al.
Journal of Comparative Effectiveness Research|March 21, 2014
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancerJoshua A Roth, Mark E Bensink, Paul V O'Donnell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 21, 2021
Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset DiabetesNaomi R M Schwartz, Lynn M Matrisian, Eva E Shrader, et al.
Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.
Future Oncology (London, England)|June 12, 2024
A descriptive analysis of real-world oncology biosimilar use in JapanJoshua A Roth, Makan Rahshenas, Grégoire Nowacki, et al.
JPGN Reports|May 11, 2023
Assessing Barriers to use of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease: A Qualitative StudyNaomi R M Schwartz, Savannah R McNichol, Beth Devine, et al.
Journal of Oncology Practice|May 7, 2015
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in MedicareJoshua A Roth, Sean D Sullivan, Bernardo H L Goulart, et al.
Plos One|October 1, 2019
Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiariesLia M Halasz, Shilpen A Patel, Jean A McDougall, et al.
Pageof 6